Search
Human botulinum neurotoxin A/B immune globulin
go.drugbank.com/drugs/DB14115ApprovedInfant botulism is a rare infectious disease occurring in infants in which _Clostridium botulinum_ colonize the large intestine and being to produce botulinum neurotoxin directly in the gut. … [L39819,L39824] BabyBIG (human-derived botulism immunoglobulin) was approved for use by the FDA in 2003[L39814] and has since been used to treat more than 2100 cases of infant botulism.
Trypsin
go.drugbank.com/drugs/DB11237ApprovedInvestigationalVet approvedTrypsin is a serine protease that plays an essential role in protein hydrolysis and absorption in mammals. … When converted from its zymogen trypsinogen, trypsin is available as an active peptide hydrolase (EC 3.4.21.4) form to cleave peptide chains, mainly at the carboxyl side of the amino acids lysine or arginine
Pegcetacoplan
go.drugbank.com/drugs/DB16694ApprovedInvestigational[A235000] Pegcetacoplan for subcutaneous use was granted FDA approval on 14 May 2021. … Pegcetacoplan is a complement inhibitor indicated in the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Rotigotine
go.drugbank.com/drugs/DB05271ApprovedInvestigationalIn 1998 Aderis licensed worldwide development and commercialization rights to Schwarz Pharma of Germany. It was approved by the European Medicines Agency in 2006 and by the FDA in 2007. … However, all Neupro patches in the United States and some of Europe were recalled in 2008 due to delivery mechanism issues. Rotigotine has been authorized as a treatment for RLS since August 2008.
Perflenapent
go.drugbank.com/drugs/DB11625ApprovedInvestigationalWithdrawnDodecafluoropentane is also known as perfluoropentane or perflenapent.
Categories: Compounds used in a research, industrial, or household settingCarboxin
go.drugbank.com/drugs/DB04657ApprovedWithdrawnA systemic agricultural fungicide and seed treatment agent.
Synonyms: 5,6-Dihydro-2-methyl-N-phenyl-1,4-oxathiin-3-carboxamideCategories: Compounds used in a research, industrial, or household settingConjugated estrogens
go.drugbank.com/drugs/DB00286ApprovedInvestigational[T475] The conjugated estrogen mixture was approved for marketing in US in 1942 based on the efficacy against certain conditions. … Both of these products are later conjugated to natrium sulfate by ester bonds in order to make them more water soluble.
Pasireotide
go.drugbank.com/drugs/DB06663ApprovedInvestigationalIt is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease.
Andexanet alfa
go.drugbank.com/drugs/DB14562ApprovedIt was developed by Portola Pharmaceuticals and was approved in in May 2018. … Rivaroxaban and apixaban are Factor Xa inhibitors that promote anticoagulation in situations where blood clotting is unfavourable, such as in deep vein thrombosis and pulmonary embolism.
Hyaluronidase (human recombinant)
go.drugbank.com/drugs/DB06205ApprovedInvestigational[A199047] Hyaluronidase was first used in prescription products in the United States on 5 May 2004.[L13338] … [L13338] The action of hyaluronidase was first described in 1936, and named in 1939.